Skip to main content

Table 1 Included patient characteristics

From: Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

   MUD/MMUD Unrelated UCB
N = 6(5)* N = 8(6)*
N N
Sex
  Male 3 (2) 4 (2)
  Female 3 4
Age
  <10 2 6 (4)
  10–20 2 1
  21–40 1 1
  >40 1 (0) 0
Diagnosis
  ALL 2 1
  AML 0 2 (1)
  Hodgkin lymphoma 1 0
  Myelodysplastic syndrome 1 1
  Multiple myeloma 1 (0) 0
  Aplastic anemia 0 2 (1)
  Fanconi anemia 0 1
  Shwachman syndrome 1 0
  Primary immunodeficiency (HLA-II defect) 0 1
Graft
  MUD 3 (2) 0
  MMUD 3 0
  Unrelated UCB 0 8 (6)
Conditioning regimen
  Myeloablative 3 5 (4)
  Non myeloablative 3 (2) 3 (2)
T cell depletion
  ATG 6 (5) 7 (5)
GVHD prophylaxis
  Ciclosporin-A + MTX 3 (2) 0
  Ciclosporin-A + MMF 2 5 (4)
  Rapamycin + MMF 1 0
  MMF 0 1
  Ciclosporin-A + corticosteroid 0 2 (1)
GVHD status prior to ADV-VST transfer
  No GVHD 1 4 (3)
  Acute GVHD grade I-II 5 (4) 1
  Acute GVHD grade III-IV 0 3 (2)
  Chronic GVHD 2 0
ADV status
  Infection 1 2 (0)
  Disease 5 (4) 6
Antiviral treatment prior to ADV-VST transfer
  Cidofovir 4 (3) 7 (5)
  Ribavirin 0 1
  None 2 0
Day ADV-VST transfer post-HSCT (days)
  <50 0 2
  50–100 2 1
  >100 3 3
  Not infused 1 2
  1. (M)MUD (mis-)matched unrelated donor, UCB umbilical cord blood, ALL acute lymphoblastic leukemia, AML acute myeloblastic leukemia, ATG antithymocyte globulin, MTX methotrexate, MMF mycophenolate mofetil, GVHD graft versus host disease, ADV adenovirus, VSTs virus-specific T cells
  2. *Numbers of patients who received ADV-VST are presented in brackets